PANCREATIC ADENOCARCINOMA

This trial is testing a personalized vaccine made from unique proteins (neoantigens) found in a person's tumor. The goal is to see if the vaccine is safe and can help slow or stop cancer growth in people with solid tumors, including pancreatic cancer. About 136 participants with …

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy with immunotherapy drugs and standard chemo to see if it's safe and what dose works best. About 74 a…

This study tests a treatment plan for people with advanced pancreatic cancer that has spread to a major artery. Participants receive chemotherapy and radiation before surgery, then more chemo after. The goal is to see if this approach is safe and helps patients live longer. The t…

This early-stage trial is testing a new drug called anvumetostat, given together with other standard chemotherapy drugs, for people with advanced cancers of the digestive system (stomach, bile ducts, or pancreas) that have a specific genetic change called MTAP deletion. The main …

This phase II trial tests an adaptive chemotherapy approach for people with pancreatic cancer that can be removed by surgery. The goal is to see if adjusting the chemo regimen based on early response can increase the number of patients who become eligible for surgery. About 32 pa…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This early-phase trial tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The radiation is given in small, spaced-out bursts along with the chemotherapy drug gemcitabine. The goal is to see if this…

This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is …

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This early-phase trial tests a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy and an immunotherapy drug (nivolumab), for people whose pancreatic cancer was removed by surgery. The goal is to see if the vaccine can be made successf…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (mFOLFIRINOX) before surgery is safe and tolerable for people with pancreatic cancer that can be removed. About 20 adults with resectable or borderline resectable pancreatic cancer will rec…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This phase 2 trial tests whether a precise, high-dose radiation technique called SBRT can lower the chance of cancer coming back in the pancreas area after surgery. The study involves 50 adults with pancreatic cancer who had surgery and are at high risk of recurrence. They will r…

This early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…

This study tests whether adding two experimental drugs (elraglusib and losartan) to standard chemotherapy (FOLFIRINOX) can prevent metastatic pancreatic cancer from becoming resistant to treatment. About 70 adults with untreated, advanced pancreatic cancer will receive the combin…

This study compares two approaches to prevent pancreatic leaks after Whipple surgery: giving antibiotics for a short time with a drug called octreotide versus giving antibiotics for a longer time. About 103 adults at intermediate or high risk for leaks will take part. The goal is…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This phase II trial is testing a combination of liposomal irinotecan (Onivyde) and FOLFOX chemotherapy given before surgery to people with pancreatic cancer that can be removed. The study includes 45 adults with early-stage disease. The goal is to see if this approach is safe and…

This study tests a drug called nimotuzumab combined with radiation and chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can better control the tumor for at least a year. The trial will enroll 30 part…

This early-phase trial is testing whether adding the diabetes drug metformin and a specific dietary supplement (including curcumin, vitamins, and other natural compounds) to standard chemotherapy (gemcitabine and abraxane) is safe and feasible for people with pancreatic cancer th…

This study tests a 3-week course of radiation (using photons or protons) combined with chemotherapy for people with pancreatic cancer that hasn't spread. The goal is to see if this shorter treatment is safe and effective, either before surgery or as the main therapy. Researchers …

This study tests whether adding a high-dose pancreatic enzyme replacement (Pancreaze) to standard care can help patients with advanced pancreatic cancer who have weight loss and trouble digesting food. About 36 adults will take the enzymes with meals and snacks for 8 weeks. The g…

This phase II trial tests whether switching from one chemotherapy regimen to another early on, before surgery, can help remove pancreatic cancer more completely. It includes patients with resectable, borderline resectable, or locally advanced unresectable pancreatic cancer. The s…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This phase II/III trial compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combo (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has BRCA1, BRCA2, or PALB2 gene mutations. T…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. It is for people with advanced pancreatic cancer that cannot be removed by surgery. The main goals are to see if the procedure is safe and possible to do. About 37 participant…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study tests whether adding the immunotherapy drug durvalumab to focused radiation (SABR) can help people with locally advanced pancreatic cancer. The goal is to shrink tumors enough to allow surgery. The trial includes 18 participants who have already received standard chemo…

This early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination fo…

This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aim…

This study aims to develop a blood test that predicts how well a patient's advanced pancreatic cancer will respond to different chemotherapy regimens. Researchers will analyze circulating tumor cells (CTCs) from 74 participants to see if the test can identify the most effective t…

This study is testing a computer model called PRISM that uses electronic health records to predict who might develop pancreatic cancer. Researchers will analyze data from over 6 million people aged 40 and older across 44 US healthcare centers. The goal is to see if the model can …

This study tests whether a supervised, at-home resistance training program using a tablet is safe and helpful for people with advanced pancreatic cancer or those recovering from surgery. About 25 participants will do guided exercises during chemotherapy or after surgery. The goal…

This study tests whether a supervised, video-based exercise program done at home during chemotherapy can help people with pancreatic cancer get stronger before surgery. About 58 patients will take part. The goal is to see if the program is safe and helps improve recovery.

This study tests whether starting palliative care early—right after diagnosis—improves quality of life for people with advanced pancreatic cancer. 250 participants receive regular visits from a palliative care team, plus referrals to exercise and nutrition experts. The goal is to…

This study looks at whether a blood test (ctDNA) can find tiny amounts of cancer left behind after pancreatic cancer surgery. Researchers will follow 150 patients who had surgery and chemotherapy to see if the test predicts who will have a relapse. The goal is to improve early de…

This study looks at a protein called DCAMKL-1, which may be a stem cell marker in pancreatic cancer. Researchers want to see how its levels change before and after treatment in 60 patients. The goal is to understand how current therapies affect this marker, not to test a new trea…

This study tests two different drug combinations in people with advanced colorectal, pancreatic, or leiomyosarcoma cancers that have not responded to standard treatments. Participants receive either olaparib plus durvalumab or cediranib plus durvalumab. The main goal is to unders…

This study looks at whether a specific surgical technique (called peri-adventitial dissection) can help surgeons remove all cancer cells during pancreatic cancer surgery. The trial involves 102 adults with non-spreading pancreatic tumors who are having a standard operation called…